^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) + depatuxizumab mafodotin (ABT-414) (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
Published date:
11/30/2020
Excerpt:
The pre-clinical efficacy of combined treatments was evaluated in multiple patient-derived xenograft (PDX) models of TNBC….Treatment with navitoclax plus ABT-414 caused a significant reduction in tumor growth in five of seven PDXs and significant tumor regression in the highest EGFR-expressing PDX.
DOI:
10.1186/s13058-020-01374-8
